AMT Medical
Series B in 2025
AMT Medical B.V., established in 2015 and located in Ede, the Netherlands, specializes in the development of innovative medical devices for heart bypass surgery. The company's flagship product, the AMT Heart Bypass System, utilizes a minimal invasive technique known as the ELANA bypass, which was invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team. This advanced technology aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, thereby improving patient outcomes and reducing complications. AMT Medical has completed the full development of its product and the production process, with all pre-clinical trials successfully concluded. The company is also preparing to initiate a clinical multi-center trial to further validate the technology's efficacy.
QDI systems
Venture Round in 2025
QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.
QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.
Photon IP is a Dutch deeptech company based in Eindhoven. It specializes in developing advanced photonics technologies for various applications.
GBM Works
Seed Round in 2024
GBM Works is a Netherlands-based company that develops offshore wind turbine foundation installation technologies. Founded in 2016 and based in The Hague, it focuses on methods for installing foundations with minimal environmental impact, including a silent installation approach designed to reduce noise pollution and disruption to marine life. The company's solutions aim to enable faster deployment of offshore wind projects while supporting sustainability goals in renewable energy.
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.
Qblox is a Dutch scaleup specializing in quantum technology, focused on developing patented solutions for the scalable control of quantum computers. The company designs and manufactures modular control hardware that simplifies the experimental setups involving qubits, employing a distributed processor architecture to enhance gate fidelities. By advancing electronics with improved noise and drift performance, Qblox enables scientists to minimize crosstalk and achieve low-latency arbitrary control flows while optimizing measurement efficiency in dynamic readout conditions. The company aims to address the scientific and engineering challenges that must be overcome to transition from prototype quantum computers to powerful, practical quantum processors.
Microsure
Series B in 2023
Founded in 2014, Microsure specializes in enhancing microsurgical procedures. Its flagship product is a motion stabilizer system designed by and for microsurgeons to overcome physical limitations and improve surgical precision. This technology has successfully been used in clinical trials, with the aim of increasing treatment options for patients.
Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.
Plasmacure
Convertible Note in 2023
Plasmacure develops a cold plasma technology to treat chronic wounds, with a focus on diabetic foot ulcers. Based in Eindhoven, the Netherlands, the company aims to stimulate healing by killing bacteria, promoting cell proliferation, and improving microcirculation, thereby reducing the risk of amputation and enhancing patient quality of life.
Sensius
Convertible Note in 2023
Sensius is a medical device company based in Rotterdam, Netherlands, founded in 2015. It develops a thermotherapy (hyperthermia) system for head and neck cancer that combines proprietary thermal technology with interactive software and integrated microwave sources. The device is designed by clinicians to tailor treatments, using consumable collars to target the head and neck region. The technology aims to augment standard cancer therapies such as radiotherapy and chemotherapy by improving treatment outcomes and quality of life while reducing associated side effects. Sensius markets its system to oncology clinics and is pursuing CE and FDA clearance, with early interest from potential purchasers as regulatory milestones are approached.
Sensius
Venture Round in 2023
Sensius is a medical device company based in Rotterdam, Netherlands, founded in 2015. It develops a thermotherapy (hyperthermia) system for head and neck cancer that combines proprietary thermal technology with interactive software and integrated microwave sources. The device is designed by clinicians to tailor treatments, using consumable collars to target the head and neck region. The technology aims to augment standard cancer therapies such as radiotherapy and chemotherapy by improving treatment outcomes and quality of life while reducing associated side effects. Sensius markets its system to oncology clinics and is pursuing CE and FDA clearance, with early interest from potential purchasers as regulatory milestones are approached.
N2 Applied
Private Equity Round in 2023
N2 Applied is a Norwegian technology company focused on enabling farmers to produce their own sustainable fertilizer through an innovative process that utilizes slurry, air, and electricity. The company is in the pre-commercial phase and has developed a technology that allows for the local production of nitrogen-rich fertilizer from liquid organic substrates, such as livestock manure. By integrating nitrogen from the atmosphere into these substrates, N2 Applied's solution not only enhances the nitrogen content but also mitigates ammonia loss and reduces greenhouse gas emissions. The company operates its head office in Oslo/Asker and maintains a test center in Svene, with additional branches in Wageningen and York. N2 Applied's scalable process aims to eliminate the lengthy and costly supply chains associated with traditional fertilizer production, facilitating a more circular farming system. This approach not only provides farmers with cost-effective and environmentally friendly fertilizer but also contributes to on-farm reductions in methane and ammonia emissions.
Dimenco
Venture Round in 2022
Dimenco develops and markets autostereoscopic 3D technology solutions. Founded in 2010, the company offers displays, components, software, content conversion services, and consultancy for professional and consumer applications.
AugmedIT B.V.
Grant in 2022
AugmedIT B.V. is a medical software company founded in 2018 and located in Amsterdam, the Netherlands. The company specializes in developing augmented and mixed reality tools that enhance surgical procedures by enabling surgeons to create holograms of patients. AugmedIT's technology focuses on applications in neurosurgery, medical education, holographic visualization, and neuronavigation, aiming to improve precision and outcomes in medical practice through innovative visualization techniques.
Dimenco develops and markets autostereoscopic 3D technology solutions. Founded in 2010, the company offers displays, components, software, content conversion services, and consultancy for professional and consumer applications.
Born from the MRCLEAN trial, NICO.LAB was founded in 2015 as a spin-off from the Amsterdam University Medical Center. Our research background continues to drive our way of thinking. The team consists of researchers, developers and experienced medical specialists to ensure we align with our clients needs. We believe connecting human & artificial intelligence will revolutionize emergency care.
Our cloud-based solution, StrokeViewer, automatically analyses brain CT scans and gives results within minutes. StrokeViewer empowers physicians in the emergency setting to provide patients with the right treatment in time.
AMT Medical B.V., established in 2015 and located in Ede, the Netherlands, specializes in the development of innovative medical devices for heart bypass surgery. The company's flagship product, the AMT Heart Bypass System, utilizes a minimal invasive technique known as the ELANA bypass, which was invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team. This advanced technology aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, thereby improving patient outcomes and reducing complications. AMT Medical has completed the full development of its product and the production process, with all pre-clinical trials successfully concluded. The company is also preparing to initiate a clinical multi-center trial to further validate the technology's efficacy.
Dawn Aerospace
Grant in 2022
Dawn Aerospace designs and manufactures reusable spacecraft and launch systems to enable frequent, sustainable access to space. The company develops same-day reusable launch vehicles that can operate with ordinary airspace and aircraft, without specialized space-launch infrastructure, and non-toxic, storable propulsion systems for satellites of all sizes, including CubeSats, offering higher performance while reducing reliance on toxic fuels. Dawn aims to provide end-to-end space transportation capabilities for deployment, positioning and return of spacecraft in a scalable, environmentally conscious manner. Founded in 2016, Dawn is based in New Zealand and the Netherlands, with research, manufacturing and testing facilities in Auckland and Delft.
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.
SolarDew is a Netherlands-based company that specializes in innovative membrane distillation technology for water desalination and purification. The firm focuses on transforming contaminated, tainted, or saline water into pure drinking water. Its modular systems are powered exclusively by solar energy, eliminating the need for external energy sources. This approach not only enhances the sustainability of water purification efforts but also empowers local entrepreneurs to establish and operate their own water treatment businesses within their communities. By leveraging renewable energy, SolarDew aims to provide accessible and safe drinking water solutions globally.
Quanturi Oy
Venture Round in 2022
Quanturi Oy is a Finnish company founded in 2016, headquartered in Espoo, with additional locations across Europe, including France, Great Britain, the Netherlands, Switzerland, Italy, and Belgium. The company specializes in developing and providing continuous monitoring solutions for fermentable products, focusing on sectors such as agriculture, forestry, and waste management. Its product offerings include wireless monitoring systems for compost temperature, grain management, and hay, as well as temperature monitoring systems applicable to various other industries. Quanturi Oy also engages in online sales of its innovative solutions, emphasizing the analysis of data associated with its connected objects.
GBM Works is a Netherlands-based company that develops offshore wind turbine foundation installation technologies. Founded in 2016 and based in The Hague, it focuses on methods for installing foundations with minimal environmental impact, including a silent installation approach designed to reduce noise pollution and disruption to marine life. The company's solutions aim to enable faster deployment of offshore wind projects while supporting sustainability goals in renewable energy.
SolarDew
Venture Round in 2022
SolarDew is a Netherlands-based company that specializes in innovative membrane distillation technology for water desalination and purification. The firm focuses on transforming contaminated, tainted, or saline water into pure drinking water. Its modular systems are powered exclusively by solar energy, eliminating the need for external energy sources. This approach not only enhances the sustainability of water purification efforts but also empowers local entrepreneurs to establish and operate their own water treatment businesses within their communities. By leveraging renewable energy, SolarDew aims to provide accessible and safe drinking water solutions globally.
Quanturi Oy is a Finnish company founded in 2016, headquartered in Espoo, with additional locations across Europe, including France, Great Britain, the Netherlands, Switzerland, Italy, and Belgium. The company specializes in developing and providing continuous monitoring solutions for fermentable products, focusing on sectors such as agriculture, forestry, and waste management. Its product offerings include wireless monitoring systems for compost temperature, grain management, and hay, as well as temperature monitoring systems applicable to various other industries. Quanturi Oy also engages in online sales of its innovative solutions, emphasizing the analysis of data associated with its connected objects.
ATRO Medical
Grant in 2022
ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of anatomically shaped polymer meniscus implants, specifically the Trammpolin. This innovative prosthesis is designed to replace damaged menisci, restoring their protective function by acting as a joint spacer and shock absorber. The Trammpolin mimics the natural meniscus, facilitating adequate load distribution within the knee joint, which can provide significant relief for osteoarthritis patients suffering from severe pain. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise from a public-private collaboration initiated in 2010 that involved various universities, private companies, and support from the Dutch government. This collaborative effort has been instrumental in the design and development of the Trammpolin prototype.
HY2Care
Venture Round in 2022
Hy2Care BV is a start-up emerging from the University of Twente in the Netherlands, focused on developing innovative treatments for osteoarthritis, a condition that affects over 100 million individuals in the Western world. The company's primary product is an injectable hydrogel designed to repair cartilage defects, specifically in the knee. This bioresorbable hydrogel consists of a two-component system made from a mixture of natural polymer conjugates that undergo a mild enzymatic reaction to form a cross-linked structure. Hy2Care aims to provide an effective treatment option for osteoarthritis, addressing a significant unmet medical need and enhancing the quality of life for patients suffering from this debilitating condition.
Hy2Care BV is a start-up emerging from the University of Twente in the Netherlands, focused on developing innovative treatments for osteoarthritis, a condition that affects over 100 million individuals in the Western world. The company's primary product is an injectable hydrogel designed to repair cartilage defects, specifically in the knee. This bioresorbable hydrogel consists of a two-component system made from a mixture of natural polymer conjugates that undergo a mild enzymatic reaction to form a cross-linked structure. Hy2Care aims to provide an effective treatment option for osteoarthritis, addressing a significant unmet medical need and enhancing the quality of life for patients suffering from this debilitating condition.
Xeltis
Venture Round in 2021
Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.
Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.
Allero Therapeutics
Grant in 2021
Allero Therapeutics is a biopharmaceutical company developing immunotherapies for immune-mediated disorders. Its core technology, Specific Oromucosal Immunotherapy (SOMIT), enables targeted delivery of antigen-specific therapies to restore immune tolerance.
N2 Applied
Venture Round in 2021
N2 Applied is a Norwegian technology company focused on enabling farmers to produce their own sustainable fertilizer through an innovative process that utilizes slurry, air, and electricity. The company is in the pre-commercial phase and has developed a technology that allows for the local production of nitrogen-rich fertilizer from liquid organic substrates, such as livestock manure. By integrating nitrogen from the atmosphere into these substrates, N2 Applied's solution not only enhances the nitrogen content but also mitigates ammonia loss and reduces greenhouse gas emissions. The company operates its head office in Oslo/Asker and maintains a test center in Svene, with additional branches in Wageningen and York. N2 Applied's scalable process aims to eliminate the lengthy and costly supply chains associated with traditional fertilizer production, facilitating a more circular farming system. This approach not only provides farmers with cost-effective and environmentally friendly fertilizer but also contributes to on-farm reductions in methane and ammonia emissions.
Founded in 2014, Microsure specializes in enhancing microsurgical procedures. Its flagship product is a motion stabilizer system designed by and for microsurgeons to overcome physical limitations and improve surgical precision. This technology has successfully been used in clinical trials, with the aim of increasing treatment options for patients.
Do you want to use your green roof to power your house? Would you like to see each wetland and rice paddy field in the world turned into a power plant without harvesting the plants? Plant-e is a company that develops and produces products in which living plants generate electricity.
The company was founded on September 14, 2009 as a spin-off from the sub-department of Environmental Technology of Wageningen University by Marjolein Helder and David Strik. Since her PhD-graduation in November 2012 Marjolein is working full-time as CEO of Plant-e. David works as an assistant professor at Wageningen University and still is an important link between scientific research and the research and development at Plant-e.
Sensius is a medical device company based in Rotterdam, Netherlands, founded in 2015. It develops a thermotherapy (hyperthermia) system for head and neck cancer that combines proprietary thermal technology with interactive software and integrated microwave sources. The device is designed by clinicians to tailor treatments, using consumable collars to target the head and neck region. The technology aims to augment standard cancer therapies such as radiotherapy and chemotherapy by improving treatment outcomes and quality of life while reducing associated side effects. Sensius markets its system to oncology clinics and is pursuing CE and FDA clearance, with early interest from potential purchasers as regulatory milestones are approached.
Qblox is a Dutch scaleup specializing in quantum technology, focused on developing patented solutions for the scalable control of quantum computers. The company designs and manufactures modular control hardware that simplifies the experimental setups involving qubits, employing a distributed processor architecture to enhance gate fidelities. By advancing electronics with improved noise and drift performance, Qblox enables scientists to minimize crosstalk and achieve low-latency arbitrary control flows while optimizing measurement efficiency in dynamic readout conditions. The company aims to address the scientific and engineering challenges that must be overcome to transition from prototype quantum computers to powerful, practical quantum processors.
Qblox is a Dutch scaleup specializing in quantum technology, focused on developing patented solutions for the scalable control of quantum computers. The company designs and manufactures modular control hardware that simplifies the experimental setups involving qubits, employing a distributed processor architecture to enhance gate fidelities. By advancing electronics with improved noise and drift performance, Qblox enables scientists to minimize crosstalk and achieve low-latency arbitrary control flows while optimizing measurement efficiency in dynamic readout conditions. The company aims to address the scientific and engineering challenges that must be overcome to transition from prototype quantum computers to powerful, practical quantum processors.
Avy is a Dutch tech company specializing in developing, manufacturing, and operating vertical takeoff and landing (VTOL) winged drones for emergency services and healthcare logistics. Its unique drone networks operate autonomously, providing rapid access to remote locations.
Avy is a Dutch tech company specializing in developing, manufacturing, and operating vertical takeoff and landing (VTOL) winged drones for emergency services and healthcare logistics. Its unique drone networks operate autonomously, providing rapid access to remote locations.
Hiber Global
Grant in 2020
Hiber Global, founded in 2016 and based in Amsterdam, Netherlands, specializes in providing satellite broadband services and affordable IoT connectivity through its Hiberband technology. The company has developed a nano-satellite platform that enables low-cost data transmission for Internet of Things (IoT) devices and sensors worldwide. This platform facilitates easy access to low-power networks, allowing users to gather small data packages from diverse monitoring devices, regardless of their location. Hiber's innovative solutions deliver actionable insights, making it a leader in next-generation IoT core infrastructure.
Plasmacure
Venture Round in 2020
Plasmacure develops a cold plasma technology to treat chronic wounds, with a focus on diabetic foot ulcers. Based in Eindhoven, the Netherlands, the company aims to stimulate healing by killing bacteria, promoting cell proliferation, and improving microcirculation, thereby reducing the risk of amputation and enhancing patient quality of life.
Plasmacure develops a cold plasma technology to treat chronic wounds, with a focus on diabetic foot ulcers. Based in Eindhoven, the Netherlands, the company aims to stimulate healing by killing bacteria, promoting cell proliferation, and improving microcirculation, thereby reducing the risk of amputation and enhancing patient quality of life.
Hiber Global
Venture Round in 2019
Hiber Global, founded in 2016 and based in Amsterdam, Netherlands, specializes in providing satellite broadband services and affordable IoT connectivity through its Hiberband technology. The company has developed a nano-satellite platform that enables low-cost data transmission for Internet of Things (IoT) devices and sensors worldwide. This platform facilitates easy access to low-power networks, allowing users to gather small data packages from diverse monitoring devices, regardless of their location. Hiber's innovative solutions deliver actionable insights, making it a leader in next-generation IoT core infrastructure.
Hy2Care BV is a start-up emerging from the University of Twente in the Netherlands, focused on developing innovative treatments for osteoarthritis, a condition that affects over 100 million individuals in the Western world. The company's primary product is an injectable hydrogel designed to repair cartilage defects, specifically in the knee. This bioresorbable hydrogel consists of a two-component system made from a mixture of natural polymer conjugates that undergo a mild enzymatic reaction to form a cross-linked structure. Hy2Care aims to provide an effective treatment option for osteoarthritis, addressing a significant unmet medical need and enhancing the quality of life for patients suffering from this debilitating condition.